On July 1, 2026, researchers from Arizona State University and Tianjin Medical University revealed significant findings on the evolutionary origins of junk DNA and its implications for cancer. This research indicates that genetic elements previously dismissed as non-functional may actually play critical roles in cancer regulation.
Understanding Junk DNA in Cancer
The term junk DNA refers to segments of DNA that do not code for proteins and were once thought to be superfluous. However, recent studies have shown that many of these elements, now identified as long noncoding RNAs (lncRNAs), are crucial in gene regulation and are linked to various cancers.
According to the study published in Science Advances, researchers conducted a comparative genomic analysis of 18,000 lncRNAs across 17 animal species, tracing their evolutionary history over nearly 500 million years.
The Evolutionary Journey of lncRNAs
The findings highlight that many cancer-associated lncRNAs originated from smaller, nonfunctional RNA fragments, evolving through increased transcription and integration into ancient cellular pathways. Michael Lynch, a professor at Arizona State University, stated, "Our findings suggest that cancer-associated long noncoding RNAs are not simply recent evolutionary additions. Instead, they can gradually become integrated into regulatory systems that have existed for hundreds of millions of years."
The study identified approximately 5,000 lncRNAs associated with at least one type of cancer, revealing their significant expansion and expression during primate evolution.
Case Study: MIR497HG
One notable lncRNA examined was MIR497HG, which emerged in a common ancestor of humans and primates around 29 million years ago. A single DNA mutation allowed MIR497HG to flourish, ultimately becoming unique to humans.
This lncRNA became intertwined with ancient regulatory networks, which are essential for processes like metabolism and programmed cell death. Misexpression of MIR497HG is linked to cancer, making it a potential biomarker for predicting cancer progression.
Experimental Validation of Findings
To further validate their findings, the research team conducted experiments on human stem cells and various cancer cell lines. They discovered that reducing MIR497HG expression promoted cancer cell growth, while restoring its expression inhibited proliferation across multiple cancer types. Wen Wei, the study's corresponding author, emphasized the importance of understanding these regulatory RNAs, stating, "Understanding how these regulatory RNAs evolved gives us a new framework for identifying biomarkers and potential therapeutic targets across multiple cancer types."
The implications of this research could revolutionize cancer diagnostics and treatment, particularly through the use of MIR497HG as a predictive biomarker, where its high expression levels in normal tissues contrast with reduced levels in cancerous conditions.
🤖 This article was rewritten by Feed and Figures' editorial AI from a report originally published by Phys.org. Facts and quotes are preserved from the original; the rewrite focuses on clarity and structure. For the unedited original, see the source link below.
